PPM1A Controls Diabetic Gene Programming through Directly Dephosphorylating PPARγ at Ser273

Area of Science:

• Molecular Biology
• Metabolic Disease Research
• Signal Transduction

Background:

• Peroxisome proliferator-activated receptor γ (PPARγ) regulates adipose tissue and is implicated in obesity-linked metabolic disorders.
• Phosphorylation of PPARγ at Ser273 by CDK5/ERK dysregulates gene expression, contributing to diabetic conditions.
• The mechanisms of PPARγ dephosphorylation at Ser273 are not well understood, limiting therapeutic development.

Purpose of the Study:

• To identify and characterize novel phosphatases involved in PPARγ dephosphorylation at Ser273.
• To investigate the role of identified phosphatases in the context of insulin resistance and obesity.
• To explore the therapeutic potential of targeting PPARγ dephosphorylation for metabolic disorders.

Main Methods:

• Biochemical assays to identify PPARγ phosphatase activity.
• In vitro and in vivo studies to validate the function of identified phosphatases.
• Analysis of gene expression using microarray and GTEx data.
• Studies in diet-induced obese (DIO) and db/db mouse models of insulin resistance.

Main Results:

• Protein phosphatase Mg2+/Mn2+-dependent 1A (PPM1A) was identified as a novel PPARγ phosphatase that directly dephosphorylates Ser273.
• PPM1A dephosphorylation of PPARγ restores dysregulated diabetic gene expression.
• PPM1A expression is significantly decreased in DIO and db/db mice, correlating negatively with pSer273.
• Human transcriptomic data show positive correlations between PPM1A and genes dysregulated by pSer273.

Conclusions:

• PPM1A directly dephosphorylates PPARγ at Ser273, counteracting the effects of aberrant phosphorylation in metabolic disease.
• Decreased PPM1A expression in insulin resistance models highlights its role in disease pathogenesis.
• PPM1A represents a promising therapeutic target for treating obesity-linked metabolic disorders.